-
Mashup Score: 5
Arvind Trindade, MD, discusses the background of a study investigating rates of pancreatic and colon cancer among younger patients.
Source: www.targetedonc.comCategories: General Medicine NewsTweet
-
Mashup Score: 3
The primary end point of overall response rate has been met in the COMPANION-002 trial of tovecimig and paclitaxel in advanced biliary tract cancer.
Source: www.targetedonc.comCategories: General Medicine NewsTweet-
In patients with advanced biliary tract cancer who progressed following first-line gemcitabine + platinum-based chemo, adding tovecimig to paclitaxel demonstrated a statistically significant improvement in ORR in the phase 2/3 COMPANION-002 trial. #gicsm https://t.co/OA7yYvG5R5
-
-
Mashup Score: 0
Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A median PFS of 6.6 months (95% CI, 5.9-7.8) in the switch maintenance arm vs 3.5 months (95% CI, 2.8-4.2) in the continued oxaliplatin-based chemotherapy arm (HR, 0.61; 95% CI, 0.48-0.79; P = .0002). #gicsm https://t.co/1VY3elRvWc
-
-
Mashup Score: 4Overall Survival Benefit Update From RATIONALE-305 - 2 month(s) ago
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab+chemotherapy vs placebo+chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma. @OncBrothers | #gicsm https://t.co/K90j6GGzo5
-
-
Mashup Score: 0
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers. #gicsm | @ILSONDavid @SunnieSKim https://t.co/XLraAxtISo
-
-
Mashup Score: 0
Perioperative and adjuvant S-1 and oxaliplatin demonstrated consistent OS and DFS benefits over adjuvant capecitabine and oxaliplatin.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Perioperative SOX improved OS compared with adjuvant CapOx (HR, 0.79; 95% CI, 0.62-1.00; Wald test P = .049); adjuvant SOX also prolonged OS vs adjuvant CapOx (HR, 0.77; 95% CI, 0.61-0.98; Wald test P = .033). #gicsm https://t.co/rDW2IwIxGO
-
-
Mashup Score: 0EC Approves Nivolumab/Ipilimumab in Frontline Unresectable HCC - 2 month(s) ago
The CheckMate 9DW trial found that nivolumab and ipilimumab elicited a median OS of 23.7 months compared with 20.6 months from lenvatinib or sorafenib.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
Nivolumab plus ipilimumab has been approved by the European Commission in the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma. #gicsm https://t.co/8w8QCOQZRQ
-
-
Mashup Score: 0Durvalumab Plus Chemotherapy Boosts EFS in Gastric/GEJ Cancer - 2 month(s) ago
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard care in this patient population.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Durvalumab plus FLOT chemotherapy significantly improved event-free survival vs. chemo alone in resectable gastric and gastroesophageal cancers, per phase 3 MATTERHORN trial (NCT04592913). #gicsm | @YJanjigianMD @MSK_DeptOfMed @Yanghee61217641 @cityofhope https://t.co/H5AiDLHgby
-
-
Mashup Score: 0
In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Patients with MSS/pMMR CRC treated with the combination regimen, the confirmed ORR was 25.0% (95% CI, 8.66%-49.10%), with 17 patients experiencing tumor reduction in target lesions, 8 of whom a reduction of 30% or greater. #gicsm https://t.co/S4yLbs74i4
-
-
Mashup Score: 0
The safety profile of trastuzumab deruxtecan in the phase 3 DESTINY-Gastric04 trial was consistent with the established safety profile of the agent.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
T-DXd exhibited a statistically significant and clinically meaningful improvement in OS vs ramucirumab plus paclitaxel in patients with second-line HER2-positive unresectable or metastatic gastric or GEJ adenocarcinoma. #gicsm https://t.co/zvg4BIb1z7
-
WATCH: Arvind Trindade, MD, (@arvind_trindade) discusses the background of a study investigating rates of pancreatic and colon cancer among younger patients. #gicsm | @JAMANetworkOpen @rutgershealth https://t.co/lg3fJygs5Z